Staar Surgical rises after Stifel upgrades to 'buy'

By Reuters News

** Shares of lensmaker Staar Surgical STAA.O rise 5.1% to $21.9 premarket

** Brokerage Stifel sees sales growth upside from adoption of company's EVO+ lens in China and recovering international demand; upgrades stock to "buy" from "hold"

** Raises PT to $31 from $28, a premium of 49% from its last close

** Says expectations for future sales are too low as growth in China remains strong and improved overseas demand

** Cites co's overlooked growth potential from its ICL technology portfolio, including opportunities in the large age related vision condition (presbyiopia) market - Stifel

** Four of 12 brokerages rate the stock "buy" or higher, seven "hold" and one "sell"; median PT is $27

** As of last close, stock down 9.6% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.